Phase II data show CEM 101 (Cempra Inc) useful against urogenital Infections and multidrug-resistant pathogens
New Phase II data on CEM 101 (solithromycin), from Cempra Inc, in patients with Infectious Diseases show that patients with gonococcal infections were treated successfully in 100% of cases. Infections were eradicated from all 22 evaluable patients (from an enrollment of 28) including from cervical, urethral, rectal and pharyngeal infection sites. It was well tolerated and was accompanied by only mild gastrointestinal effects.
Studies also show that the drug is also active against Mycoplasma genitalium, a pathogen that is increasingly resistant to treatment with any antibiotics. In addition, CEM 101 demonstrates superior activity to azithromycin against Legionella pneumophila, a serious pnuemonia pathogen, and against enterococci, a pathogen with few treatment options. Data was presented at the European Congress of Clinical Microbiology and Infectious Diseases.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins